Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 EUR | -0.71% | +3.35% | +29.91% |
04-17 | OSE: licensing agreement with AbbVie enters into force | CF |
04-17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.38M 191M | Sales 2024 * | 37.83M 40.45M 3.24B | Capitalization | 120M 128M 10.27B |
---|---|---|---|---|---|
Net income 2023 | -23M -24.59M -1.97B | Net income 2024 * | -5M -5.35M -428M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.04M 2.89B | Net Debt 2024 * | 46.6M 49.83M 3.99B | EV / Sales 2024 * | 4.4 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-12.9
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | -0.71% | ||
1 week | +3.35% | ||
Current month | +14.40% | ||
1 month | +12.66% | ||
3 months | +41.30% | ||
6 months | +33.81% | ||
Current year | +29.91% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 16/11/04 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 30/05/16 |
Director of Finance/CFO | - | 30/04/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 16/11/04 | |
Director/Board Member | 66 | 21/06/23 | |
Director/Board Member | 66 | 17/02/22 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 5.56 | -0.71% | 87,408 |
25/04/24 | 5.6 | -0.71% | 158,909 |
24/04/24 | 5.64 | -5.53% | 240,936 |
23/04/24 | 5.97 | 0.00% | 376,959 |
22/04/24 | 5.97 | +10.97% | 410,921 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.91% | 128M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OSE Stock